Testing to treatment of BRAF-mutant metastatic NSCLC In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients. The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment. The experts also discuss how to treat patients who have co-mutations detected during testing. This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC. Key clinical takeaways: Test all patients irrespective of histology and smoking history Test upfront so that more efficacious agents can be used earlier in the patient journey Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/ Follow us on social media: LinkedIn: https://www.linkedin.com/company/lungconnect/ X: https://x.com/lung_connect This content is intended for healthcare professionals outside of the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This podcast is developed by https://cor2ed.com/ Published November 2024 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related